Search

Your search keyword '"Methotrexate pharmacology"' showing total 240 results

Search Constraints

Start Over You searched for: Descriptor "Methotrexate pharmacology" Remove constraint Descriptor: "Methotrexate pharmacology" Journal cancer research Remove constraint Journal: cancer research
240 results on '"Methotrexate pharmacology"'

Search Results

1. Overexpression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors.

2. Geminin functions downstream of p53 in K-ras-induced gene amplification of dihydrofolate reductase.

3. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.

4. Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells.

5. MDM2 regulates dihydrofolate reductase activity through monoubiquitination.

6. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.

7. Identification and characterization of genetic variation in the folylpolyglutamate synthase gene.

8. Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma.

9. ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates.

10. Cancer chemotherapy by deoxynucleotide depletion and E2F-1 elevation.

11. Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients.

12. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.

13. p14ARF expression increases dihydrofolate reductase degradation and paradoxically results in resistance to folate antagonists in cells with nonfunctional p53.

14. Inhibition of induced chemoresistance by cotreatment with (E)-5-(2-bromovinyl)-2'-deoxyuridine (RP101).

15. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.

16. Levels of phospholipid metabolites in breast cancer cells treated with antimitotic drugs: a 31P-magnetic resonance spectroscopy study.

17. Effects of overexpression of gamma-Glutamyl hydrolase on methotrexate metabolism and resistance.

18. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity.

19. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.

20. Anthracyclines trigger apoptosis of both G0-G1 and cycling peripheral blood lymphocytes and induce massive deletion of mature T and B cells.

21. Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate-alpha-peptide prodrugs.

22. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2.

23. Modulation of the cytotoxicity of 3'-azido-3'-deoxythymidine and methotrexate after transduction of folate receptor cDNA into human cervical carcinoma: identification of a correlation between folate receptor expression and thymidine kinase activity.

24. Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation.

25. Selective tumor apoptosis by MF13, L-prolyl-L-m-[bis(chloroethyl)amino]-phenylalanyl-L-norvaline ethyl ester, a new sarcolysin containing tripeptide.

26. Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability.

27. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs.

28. Overexpression of p21waf1 leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells.

29. Cancer invasion and micrometastasis visualized in live tissue by green fluorescent protein expression.

30. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.

31. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells.

32. Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells.

33. Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy.

34. Attenuation of interleukin 2-induced pulmonary vascular leak syndrome by low doses of oral methotrexate.

35. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.

36. Heterogeneity in the mitotic checkpoint control of BALB/3T3 cells and a correlation with gene amplification propensity.

37. Effect of modulators on 5-fluorouracil metabolite patterns in murine colon carcinoma determined by in vitro 19F nuclear magnetic resonance spectroscopy.

38. Novel 6,5-fused ring heterocyclic antifolates: biochemical and biological characterization.

39. Increased methotrexate resistance and dhfr gene amplification as a consequence of induced Ha-ras expression in NIH 3T3 cells.

40. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.

41. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.

42. The riminophenazine agents clofazimine and B669 inhibit the proliferation of cancer cell lines in vitro by phospholipase A2-mediated oxidative and nonoxidative mechanisms.

43. Inability of leucovorin to rescue a naturally methotrexate-resistant human soft tissue sarcoma cell line from trimetrexate cytotoxicity.

44. Time dependence of DNA lesions and growth inhibition by ICI D1694, a new quinazoline antifolate thymidylate synthase inhibitor.

45. Expression and characterization of mucins associated with the resistance to methotrexate of human colonic adenocarcinoma cell line HT29.

46. Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo.

47. Intrinsic resistance to methotrexate in human soft tissue sarcoma cell lines.

48. Differentiation of choriocarcinoma cell line (JAr).

49. Cell cycle-related expression of p120 nucleolar antigen in normal human lymphocytes and in cells of HL-60 and MOLT-4 leukemic lines: effects of methotrexate, camptothecin, and teniposide.

50. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate.

Catalog

Books, media, physical & digital resources